#United States #New York #Class Action #Soleno Therapeutics #DCCR

Soleno Therapeutics Shareholder Alert: Class Action Opportunity

Recently, The Gross Law Firm issued a critical notice to investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning potential legal actions for those who purchased shares during a specific time frame. This development comes in light of allegations regarding misleading statements related to the clinical trial program of Soleno's DCCR (diazoxide choline extended-release tablets). The firm encourages shareholders who experienced losses to connect with them regarding a possibility to be appointed as lead plaintiff in a class action lawsuit.

Background on the Allegations

Between March 26, 2025, and November 4, 2025, Soleno Therapeutics' management is accused of issuing materially false and misleading statements regarding the safety and viability of DCCR. The allegations specify that the clinical trial results were misrepresented, downplaying significant safety concerns, particularly issues related to fluid retention among trial participants. Such omissions allegedly resulted in a substantial risk regarding the administration of the drug in treating hyperphagia in patients with Prader-Willi syndrome (PWS). This potentially positions the medication as having greater safety risks than disclosed, prompting concern among investors regarding its commercial viability.

The situation is compounded by claims of undisclosed risks associated with the likelihood of adverse events following the drug's long-term use, which could have significant repercussions for patient adoption, prescriber willingness, and potential regulatory actions that threaten the company's reputation and financial standing.

What Should Shareholders Do?

The deadline to register as a lead plaintiff for this impending class action is May 5, 2026. Shareholders are advised to act promptly and secure their opportunity to seek recovery for losses sustained. By registering their information, they will automatically be enrolled in a monitoring system that keeps them updated on the case's progress. Participation in the case does not entail any costs, ensuring that investors can proceed without financial risk.

The Gross Law Firm emphasizes their commitment to protecting the rights of investors who have faced financial strain due to corporate misrepresentation. Their mission reflects a broader goal of promoting ethical business practices and accountability among publicly traded companies.

Why Choose The Gross Law Firm?

With a reputation as a leading class action law firm nationally, The Gross Law Firm stands out due to its relentless pursuit of justice on behalf of investors affected by unscrupulous corporate actions. Their legal team provides expertise in navigating the complexities of securities law, ensuring that shareholders have a robust platform to seek recovery for their losses. Previous legal successes highlight their dedication to investor rights, and their commitment remains strong in the face of financial misconduct.

For affected shareholders of Soleno Therapeutics seeking to book an appointment for the class action lawsuit, or for further inquiries, please contact:

• - The Gross Law Firm

15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

In a moment when financial recoveries and accountability are paramount, this alert serves as a crucial reminder for investors to take action with respect to their investments in Soleno Therapeutics. Stay informed, stay protected, and act before the deadline closes.